洛佩拉胺诱导的心室节律失常和发作
Azalfa Lateef1, Ufuk Vardar2, Drew Sanclemente3
1Department of Internal Medicine, Mayo Clinic Florida, Jacksonville, Florida, USA.
JACC. Case reports
|November 28, 2025
概括
高剂量的洛佩拉胺,一种非处方药,可以导致严重的心脏毒性,包括获得的长QT综合征和心室心律不整. 这一案例凸显了过度使用洛佩拉可能导致危及生命的心脏和神经事件的可能性.
科学领域:
- 心脏病学 心脏病学
- 临床毒理学 临床毒理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 洛佩拉胺是一种非处方药,通常用于治疗腹.
- 高剂量的洛佩拉米德可以导致显著的毒性.
- 戒断阿片类药物是高剂量洛佩拉胺滥用的潜在原因.
研究的目的:
- 报告洛佩拉胺诱导心脏毒性的病例.
- 为了强调高剂量洛佩拉使用的潜在危害.
- 讨论洛佩拉胺毒性的临床表现和管理.
主要方法:
- 一名42岁的男子出现多态心室动脉冲动症的病例报告.
- 对呈现心电图结果的分析.
- 对心室心律失常和阿片类药物使用障碍治疗的审查.
主要成果:
- 患者在每天高剂量洛佩拉胺使用 (100-200毫克) 后出现多态心室性心力衰竭.
- 电心电图显示了一个广泛的复杂节奏转换为鼻节奏,具有延长的QT间隔.
- 对于心室动和多态心室动脉冲动需要植入心脏除器疗法.
结论:
- 洛佩拉米德,即使是非处方药,也可能导致危及生命的心脏毒性.
- 获得的长QT综合征和心室节律失常是潜在的表现.
- 神经毒性,如发作,也可能发生在高剂量的洛佩拉胺.
相关概念视频
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
599
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
599
Antiepileptic Drugs: Potassium Channel Activators
611
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
611
Drugs for Treatment of Constipation-Predominant IBS
680
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
680
Antiepileptic Drugs: Sodium Channel Blockers
1.6K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
1.6K
Drugs for Treatment of Diarrhea-Predominant IBS
599
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
599
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
1.2K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.2K


